Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes

In Brief Sodium–glucose cotransporter 2 (SGLT2) inhibitors and incretin-based therapies (dipeptidyl peptidase-4 [DPP-4] inhibitors and glucagon-like peptide-1 [GLP-1] receptor agonists) are widely used to treat patients with type 2 diabetes. In clinical and real-world studies, canagliflozin, an SGLT...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratley, Richard E., Cersosimo, Eugenio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2017
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510927/
https://www.ncbi.nlm.nih.gov/pubmed/28761216
http://dx.doi.org/10.2337/cd16-0063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510927/
https://www.ncbi.nlm.nih.gov/pubmed/28761216
http://dx.doi.org/10.2337/cd16-0063

Ejemplares similares